Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

BMS to Set China Price of Opdivo, a PD-1 Drug, at 50% of US Cost

publication date: Aug 22, 2018

Bristol-Myers Squibb will set the China price of Opdivo, its PD-1 lung cancer treatment, at half the US price, according to news sources. The US price is roughly $150,000, but the China price will be a still-high $84,000, which would make Opdivo one of the most -- if not the most -- expensive drugs in China. BMY expects to launch the drug in China before the end of September. More details....

Stock Symbol: (NYSE: BMY)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.